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GSK3-mediated raptor phosphorylation supports amino-acid-dependent
mTORC1-directed signalling
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Harinder S. Hundal*1
*Division of Cell Signalling & Immunology, James Black Centre, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
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The mammalian or mechanistic target of rapamycin (mTOR)
complex 1 (mTORC1) is a ubiquitously expressed multimeric
protein kinase complex that integrates nutrient and growth factor
signals for the co-ordinated regulation of cellular metabolism
and cell growth. Herein, we demonstrate that suppressing
the cellular activity of glycogen synthase kinase-3 (GSK3),
by use of pharmacological inhibitors or shRNA-mediated
gene silencing, results in substantial reduction in amino acid
(AA)-regulated mTORC1-directed signalling, as assessed by
phosphorylation of multiple downstream mTORC1 targets. We
show that GSK3 regulates mTORC1 activity through its ability
to phosphorylate the mTOR-associated scaffold protein raptor
(regulatory-associated protein of mTOR) on Ser859. We further
demonstrate that either GSK3 inhibition or expression of a S859A
mutated raptor leads to reduced interaction between mTOR
and raptor and under these circumstances, irrespective of AA
availability, there is a consequential loss in phosphorylation of
mTOR substrates, such as p70S6K1 (ribosomal S6 kinase 1) and
uncoordinated-51-like kinase (ULK1), which results in increased
autophagic flux and reduced cellular proliferation.
Key words: amino acid, autophagy, growth, insulin, L-type
(leucine) amino acid transporter 1 (LAT1), leucine, p70S6K1,
proliferation, transcription factor EB (TFEB), sodium-coupled
neutral amino acid transporter 2 (SNAT2), uncoordinated-51-like
kinase (ULK1).
INTRODUCTION
The mammalian or mechanistic target of rapamycin (mTOR)
complex 1 (mTORC1) is a multimeric protein assembly
composed of mTOR, mLST8 (mammalian lethal with
SEC13 protein 8), proline-rich Akt substrate of 40 kDa
(PRAS40) and raptor (regulatory-associated protein of mTOR)
that integrates mitogenic and nutrient [amino acid (AA)]
signals to regulate diverse cellular responses, including
mRNA translation, cell growth/proliferation, metabolism
and autophagy [1,2]. Activation of mTORC1 is crucially
dependent upon a small G-protein called Rheb (Ras homolog
enriched in brain), whose intrinsic GTPase activity is
inhibited by the GTPase-activating protein (GAP) activity of
the tuberous sclerosis complex (TSC1/2) [3]. TSC1/2 is
itself subject to regulation by the IRS1–PI3K–Akt signalling
axis whose activation by mitogenic stimuli results in Akt-
mediated phosphorylation of TSC2 and inhibition of its GAP
activity that, in turn, aids accumulation of active Rheb and
a consequential increase in mTORC1 activity [4]. In contrast,
stimulation of mTORC1 in response to nutrient availability occurs
independently of the TSC1/2 complex [5] and is thought to involve
translocation of mTORC1 from the cytosol to the lysosomal
membrane, where mounting evidence suggests that sensing of
AA sufficiency occurs. Members of the Rag family of small G-
proteins have been implicated in the lysosomal recruitment of
mTORC1 and operate as heterodimers (RagA–RagB and RagC–
RagD) which promote redistribution of mTORC1 to lysosomal
membranes in response to AA provision [6]. Rags are tethered
to the lysosomal surface by interactions with two heteromeric
protein complexes; the Ragulator (Rag regulator) complex [6]
and the vacuolar H+ -ATPase [7]. The Rag heterodimer is most
active when the RagA–RagB component is GTP-loaded and the
RagC–RagD component is in its GDP-bound form. In this state,
the Rag heterodimer is able to bind mTORC1 allowing it to make
contact with Rheb-GTP at the lysosomal surface where it becomes
activated [7]. Once activated, the catalytic domain of mTOR
phosphorylates substrates associated with raptor, which functions
as a crucial scaffold placing bound substrates in close proximity to
mTOR and enabling modulation of diverse downstream processes.
Whereas the Ragulator possesses guanine-nucleotide-exchange
factor (GEF) activity towards RagA/B to facilitate GDP exchange
for GTP, hydrolysis of bound GTP is influenced by another protein
complex, GTPase-activating protein towards Rags (GATOR1),
which has GAP activity towards RagA–RagB [8]. Very recent
work has now identified a lysosomal membrane AA transporter
belonging to the solute carrier 38 (SLC38) family, SLC38A9
[also known as sodium-coupled neutral amino acid transporter 2
(SNAT9)], as a putative AA sensor whose occupancy by substrate
AAs is thought to signal AA sufficiency to mTORC1 via its
interaction with the Rag–Ragulator complex [9,10].
A further level of control of mTOR activity may be afforded
by the stimulus (insulin and/or AA)-dependent regulation of
TSC localization [11,12]. Insulin and AA provision have been
shown to induce TSC dissociation from lysosomal membranes,
whereas removal of either stimulus facilitates greater lysosomal
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association of the complex that will have a negative impact on
Rheb activity, thereby providing a mechanism for repressing or
‘switching-off’ mTOR activity. However, despite the significant
advances that have been made in our understanding of how
mTORC1 is activated, certain aspects of the current model require
further refinement in the light of recent studies demonstrating:
(i) that AAs can induce mTORC1 activation without changing
the guanyl nucleotide charging of Rag GTPases [13], and
(ii) that leucine can promote mTORC1 activity independently
of lysosomal mTOR localization [14]. Furthermore, given the
diversity of signals that mTORC1 is able to integrate and the
range of downstream cellular responses that it regulates, it is
highly likely that other, hitherto unidentified, regulatory proteins
are involved in controlling the fidelity with which activation and
signalling of mTORC1 is achieved. Indeed, in addition to AA
sensing and recruitment of the mTORC1 protein ensemble to the
lysosomal membrane, the covalent modulation of key components
of mTORC1 may serve as a crucial determinant of mTORC1
signalling. Previous work has highlighted, for example, that raptor
undergoes multi-site phosphorylation upon catalytic activation
of mTOR and that this may induce conformational changes in
mTORC1 that permit phosphorylation of raptor-bound substrates
by mTOR [15]. One of these sites on raptor, Ser863, is postulated
to be phosphorylated by mTOR itself and is considered necessary
for promoting the hierarchical phosphorylation of neighbouring
residues (Ser859 and Ser855) by other, as yet, unidentified protein
kinases [15]. Whilst raptor can be phosphorylated by RSK
(p90 ribosomal S6 kinase) [16], AMPK (AMP-activated protein
kinase) [17] and CDK1/cdc2 (cyclin dependent kinase 1) [18],
there is no evidence to suggest that these kinases target these sites
to support nutrient-dependent regulation of mTORC1. Another
potential candidate kinase is glycogen synthase kinase 3 (GSK3).
Recent evidence has highlighted that GSK3 positively regulates
mTORC1 activity in MCF-7 breast cancer cells [19] and that it
supports G2/M cell cycle progression through its ability to enhance
mitotic raptor phosphorylation and mTORC1 activity [20].
In the present study, we show that raptor can be phosphorylated
by GSK3 on Ser859 and that GSK3 plays a permissive role in
AA-induced activation of mTORC1, given that pharmacological
inhibition or silencing of GSK3 results in a striking reduction
in AA-stimulated mTORC1 signalling. We also demonstrate
that, although GSK3 inhibition/silencing has no detectable effect
upon lysosomal mTOR localization or upon expression of key
protein components of mTORC1, loss of Ser859 phosphorylation
is associated with reduced interaction of raptor with mTOR
resulting in a consequential reduction in the phosphorylation of
downstream targets such as S6K1, 4E-BP1 (ukaryotic initiation
factor 4E-binding protein) and ULK1 (uncoordinated-51-like
kinase). This loss in mTORC1-mediated S6K1 and ULK1




Antibodies directed against GSK3α/β were purchased from
Santa Cruz Biotechnology. Anti-GSKβ antibody was purchased
from BD Biosciences. Anti-glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) and anti-FLAG antibodies were
purchased from Sigma–Aldrich. Anti-LAMP2 antibody was
from Abcam. Antibodies against GSK3α and raptor were
obtained from the Division of Signal Transduction Therapy
(DSTT), University of Dundee. Anti-light chain 3 (LC3)
antibody was purchased from MBL. Anti-puromycin antibody
was from Kerafast. Antibodies against raptor-Ser863 and raptor-
Ser859 were kindly supplied by Dr Diane Fingar (University of
Michigan, Ann Arbor, MI, U.S.A.). Alexa-Fluor 488-conjugated
anti-mouse and anti-rabbit and Alexa-Fluor 594-conjugated anti-
mouse secondary antibodies were from Life Technologies as was
all cell culture medium. All other antibodies were purchased from
Cell Signaling Technology. Rapamycin, insulin, SB415286 and
SB216763 were purchased from Tocris Biosciences. CT99021
was a gift from Dr Calum Sutherland (University of Dundee).
Roscovitine was from Merck. Bafilomycin A1 was from Enzo
Life Sciences. [32P]ATP and Protein G–Sepharose were from
GE Healthcare. Cycloheximide and puromycin were from
Abcam. Ku-0063794 was a gift from Professor Doreen Cantrell
(University of Dundee). Oligonucleotides were purchased from
the University of Dundee Oligo Synthesis Service. All other
reagents and chemicals were purchased from either Sigma–
Aldrich or VWR, unless stated.
Cell culture, gene-silencing and transfection
L6 rat skeletal muscle cells were grown as described previously
in α-MEM containing 2% (v/v) FBS (Biosera) [21]. Experiments
were carried out at the myotube stage, typically 7 days post-
seeding. AA starvations were carried out by incubation in EBSS.
AA resupply was carried out by incubation in EBSS containing
a complete mix of AAs at plasma physiological concentrations.
Other pharmacological inhibitors were added as described in the
text and figure legends. Stable L6 GSK3α/β double knockdown
cell lines were generated in a similar manner to that described
previously using the oligonucleotides shown in Supplementary
Table S1 [22,23]. Briefly, oligonucleotides were annealed as
described previously and then cloned into the AgeI/EcoRI sites
of either pLKO.1-puro (GSK3α hairpins only) or a pLKO.1-
puro vector in which the puromycin-resistance gene had been
removed and replaced with a sequence coding for hygromycin
resistance (termed pLKO.1-hygro) at the BamHI/KpnI sites
(GSK3β hairpins only). Generation of recombinant lentiviruses
and transduction of L6 cell cultures were carried out as
described previously [22] and stable cell lines were established
by incubation with either 3 μg/ml puromycin or 15 μg/ml
hygromycin. GSK3α knockdown cell lines were established first
and then the GSK3β hairpins were transduced into these cell lines
and re-selected. Control cell lines contain both the hygromycin-
and the puromycin-resistant viruses containing a control non-
targeting sequence made with the oligonucleotides shown in
Supplementary Table S1. Stable cell lines were established using
early passage cells and, once established, were only used for
a maximum of five passages. Human embryonic kidney (HEK)
293T, U20S and HeLa cells were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) containing 10% FBS. HEK293T
cells were transfected with pCMV–raptor wild-type (wt) and
mutant constructs (8 μg of DNA/10 cm dish; 3 μg of DNA/six-
well plate) using polyethyleneimine (PEI) with a 3:1 PEI/DNA
ratio. Cells were used 48 h post-transfection. The effects of
GSK3–mTORC1 inhibition upon the exponential growth phase
of cells was monitored by seeding HEK293T cells at a seeding
density of 3.5 × 104 cells per well of a six-well dish. Cells were
treated with vehicle control, SB415286 or rapamycin 24 h post
seeding and then for periods up to 72 h with fresh medium and
inhibitors being replaced every 24 h. Cells were trypsinized and
counted in triplicate using a Neubauer counting chamber.
Plasmids and mutagenesis
The vector pCMV–FLAG–raptor, containing human wt raptor
sequence, was kindly provided by the DSTT (University of
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Dundee). Oligonucleotides shown in Supplementary Table S1
were used to create the S859A and S863A mutants using KOD
Hot Start DNA polymerase (Novagen). The mutated raptor DNA
regions were fully sequenced.
Preparation of whole-cell lysates and immunoblotting
Cells were incubated as described in the text and figure
legends. After treatment, cells were washed twice with ice-
cold PBS and then lysed as described previously [21]. Protein
concentrations in the final prepared lysates were determined
using the Bradford method [24]. Cell lysates were separated
using SDS/PAGE, transferred onto PVDF (Millipore) membranes
and then immunoblotted with the appropriate primary antibodies
followed by incubation with appropriate horseradish peroxidase
(HRP)-conjugated anti-IgG antibody. Proteins were detected
using ECL using exposure to autoradiographic film (Kodak).
Quantification of immunoblots was carried out with ImageJ
(NIH).
GSK3 kinase activity assays
L6 cells were treated as described in the text and cells
extracted from 10 cm dishes using lysis buffer [21]. GSK3 was
immunoprecipitated from 100 μg of cell lysate for 2 h using
Protein G–Sepharose beads that had previously been conjugated
to isoform-specific antibodies for GSK3α and GSK3β. Antibody–
bead complexes were then washed twice in lysis buffer containing
an additional 0.5 M sodium chloride and twice in wash buffer
(50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA and 0.1% β-
mercaptoethanol). Beads were resuspended in a final volume of
50 μl of assay buffer {50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA,
0.1% β-mercaptoethanol, 50 mM magnesium acetate, 0.2 mM
phospho-GS peptide (YRAAVPPSPSLSRHSSPHQSEDEEE),
100 μM non-radiolabelled ATP and 2.7 μCi of [32P]ATP} and
incubated shaking for 30 min at 30 ◦C. Thirty microlitres of the
reaction mix was spotted on to P81 filter paper. Papers were
washed three times in 1% phosphoric acid then once in acetone
before being dried and [32P]ATP incorporation was measured
using a Beckman LS 6000IC scintillation counter.
RNA extraction, cDNA synthesis and real-time PCR
RNA was extracted from cells using TriReagent (Sigma–Aldrich)
according to the manufacturer’s instructions. First-strand cDNA
was synthesized from 1 μg of total RNA using oligo(dT)15 primers
and Moloney murine leukaemia virus reverse transcriptase
(Promega) according to the manufacturer’s instructions.
Real-time quantitative PCR was performed using a StepOne
Plus real-time thermocycler (Applied Biosystems), SYBR Green
JumpStart kit (Sigma–Aldrich) and primers targeting GSK3α,
GSK3β, L-type (leucine) amino acid transporter 1 (LAT1),
SNAT2 and GAPDH as a control. Sequences of primers used
are shown in Supplementary Table S1. PCR conditions were
as follows: initial denaturation at 95 ◦C for 2 min followed by
40 cycles of 95◦C for 15 s, 55 ◦C for 15 s and extension at
68 ◦C for 30 s. The ratio of GSK3, LAT1 and SNAT2 expression
to GAPDH mRNA expression was calculated using a method
described previously [25].
Quantification of LC3 puncta and TFEB immunofluorescence
U2OS cells were seeded out on to glass coverslips. Twenty-
four hours later, cells were treated with AA/inhibitors as
indicated in the figure legends, except in the final 15 min when
cells were incubated in the absence or presence of 100 nM
bafilomycin A1 (Enzo Life Sciences). Cells were subsequently
fixed in 3.7% formaldehyde, permeabilized with 0.2% NP-40
and stained with mouse anti-LC3 (1:1000, MBL International
Corporation) followed by Alexa Fluor 488-conjugated anti-mouse
secondary antibody (Life Technologies). Slides were stained
and mounted using ProLong Gold antifade reagent with DAPI
(Life Technologies) to enable localization of nuclei and viewed
on a Nikon Eclipse Ti widefield microscope and quantified
from three fields of view (with a minimum of 25 cells per
field) per condition utilizing NIS-Elements software. For TFEB
(transcription factor EB) localization studies, HeLa cells were
seeded on to glass coverslips. At approximately 70% confluency,
cells were transfected with 2 μg of the plasmid pcDNA5-FRT/TO-
GFP TFEB wt (a gift from the laboratory of Professor Carol
MacKintosh, University of Dundee) using the Metafectene +
transfection reagent (Biontex). Twenty-four hours later, cells were
treated as described in the text and figure legends, fixed in 4%
paraformaldehyde for 10 min, then mounted in Vectashield DAPI-
containing mounting medium (Vector Laboratories). For mTOR
localization studies, HeLa cells were seeded on to coverslips
and grown until approximately 70% confluent. Treatments
were carried out as described in the text and figure legends.
Cells were fixed in 4% paraformaldehyde for 10 min then
permeabilized for 10 min with 1% Triton X-100. Blocking was
carried out for 1 h at room temperature (RT) in 10% goat
serum/0.2% BSA/PBS then primary antibodies were incubated
on the coverslips overnight at 4 ◦C in a humidified chamber.
Following washing, the appropriate secondary antibodies were
incubated on the coverslips for 1 h at RT. Coverslips
were washed and mounted in VectaShield DAPI-containing
mounting medium. Cells were imaged on a Zeiss LSM 700
confocal microscope and images were quantified using Volocity
software (PerkinElmer) version 6.3.0. Briefly, DAPI-stained
nuclei and GFP-transfected cells were identified using Otsu’s
method, nuclei areas were subtracted from the identified cells
to give a cytoplasmic GFP intensity and this was used to give a
nuclear/cytoplasmic intensity ratio for each image. Ten images
were taken for each treatment.
Protein synthesis
Protein synthesis was measured as described by Kelleher et al.
[26] by assaying the incorporation of puromycin into newly
synthesized peptides. Briefly, cells were pre-treated as described
in the figure legends with AAs, insulin or cycloheximide
(50 μg/ml) prior to incubation in the absence or presence of 1 μM
puromycin for 30 min. At the end of this period, cells were lysed
and lysates were subjected to SDS/PAGE and immunoblotting
of PVDF membranes carried out overnight at 4 ◦C with a mouse
monoclonal anti-puromycin antibody [1 μg/ml in Tris-buffered
saline with 0.01% (v/v) Tween 20 and 5% (w/v) non-fat
dried milk] followed by incubation with goat anti-mouse HRP-
conjugated secondary antibody.
LC–MS/MS
HEK293T cells were treated with or without SB415286 for 1 h
and lysed with lysis buffer containing 50 mM HEPES, pH 7.4,
150 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol, 0.5% (v/v) NP-
40, 1 mM DTT, 1 mM PMSF and phosphatase inhibitors. Lysates
were clarified by centrifugation at 21000 g for 10 min at 4 ◦C.
Raptor was directly immunoprecipitated using an antibody raised
against human raptor (residues 1–20). Samples were resolved
by SDS/PAGE, and acrylamide gels were subsequently stained
for protein using Instant BlueTM Coomasssie Blue (Expedeon) as
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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per the manufacturer’s guidelines. Bands corresponding to raptor
were excised and diced into small cubes (∼1 mm) and transferred
to a clean Eppendorf per band.
Gel pieces underwent sequential washes (0.5 ml for 10 min
each on a vibrating platform) with water, 50% acetonitrile
(ACN), 100 mM ammonium bicarbonate (NH4HCO3) and 50%
ACN/50 mM NH4HCO3. Samples were alkylated in-gel; first
samples were reduced by addition of 75 μl of 10 mM DTT
in 0.1 M NH4HCO3 for 45 min at 65 ◦C. The supernatant was
removed and then 75 μl of 50 mM iodoacetamide in 0.1 M
NH4HCO3 was used to alkylate samples for 20 min at RT.
Supernatant was removed and gel pieces were washed with
50 mM NH4HCO3 + 50% ACN. Gel pieces were incubated
with 0.3 ml of ACN for 15 min at RT; this was removed
by centrifugal evaporation (SpeedVacTM, Thermo Scientific)
to dry the gel pieces. To digest proteins, 30 μl of 25 mM
triethylammonium bicarbonate containing 5 μg/ml trypsin was
added to gel pieces and incubated shaking for 30 min at RT.
Water was added, if required, to completely cover gel pieces,
and samples were left shaking at 1100 rev/min for 16 h at RT in a
Thermomixer® (Eppendorf). An equal volume of ACN was then
added to the gel pieces to extract peptides and incubated at 1100
rev/min for 15 min at RT. The supernatant was removed and dried
by centrifugal evaporation. During this time, 100 μl of 50%ACN
and 2.5% formic acid was added to the gel pieces and shaken at
1100 rev/min at RT. The supernatant was added to the initial dried
extract and dried once more by centrifugal evaporation. Once
completed samples were submitted to the MRC proteomics and
MS team for analysis by LC–MS/MS.
mTOR and raptor immunoprecipitation
HEK293T cells were cultured in 10 cm plates and treated
as described in figure legends. Cells were washed twice in
ice-cold PBS and lysed in HEPES/CHAPS buffer (40 mM
HEPES, pH 7.4, 120 mM NaCl, 1 mM EDTA and 0.3%CHAPS)
supplemented with 1 mM DTT, 1 mM PMSF and phosphatase
inhibitors. Endogenous mTOR was immunoprecipitated from
2 mg of lysate using 10 μg of anti-mTOR antibody (obtained
from the DSTT, University of Dundee) and 25 μl of Protein
G–Sepharose. Beads were washed with HEPES/CHAPS lysis
buffer, and proteins were eluted and analysed by Western
blotting. Alternatively, for immunoprecipitation of FLAG–raptor,
HEK293T cells expressing wt or mutant FLAG–raptor were
treated and lysed as described above. FLAG–raptor variants were
immunoprecipitated from 1 mg of lysate by incubation with 4 μg
of anti-FLAG antibody (Sigma) for 2 h. After 1 h of incubation,
30 μl of Protein G–Sepharose beads were added. Beads were
washed twice with HEPES/CHAPS lysis buffer and 380 mM NaCl
and twice with HEPES/CHAPS lysis buffer before resuspending
in SDS sample buffer.
Analysis of GSK3 activity and raptor-associated mTORC1 kinase
activity
L6 cells were treated as described in the figure legends and cells
were extracted from 10 cm dishes using lysis buffer [21]. GSK3
was immunoprecipitated from cell lysates, and isoform-specific
GSK3 activity assayed as described above. For analysis of raptor-
associated mTOR kinase activity, cells were treated and lysed
with HEPES/CHAPS buffer as described above. FLAG-tagged
raptor was immunoprecipitated from 2 mg of lysate using anti-
FLAG antibodies and 25 μl of Protein G–Sepharose as described
above. Beads were washed with HEPES/CHAPS lysis buffer and
subsequently resuspended in 30 μl of kinase assay buffer (25 mM
HEPES, 50 mM KCl, 10 mM MnCl2, 200 μM ATP and 1 mM
DTT). Kinase reactions were carried out for 10 min at 30 ◦C
in the presence of 3 μg of recombinant kinase-dead p70S6K
(DSTT, University of Dundee). Reactions were terminated with
10 μl of 4× SDS sample buffer and p70S6K phosphorylation was
visualized by SDS/PAGE and subsequent immunoblotting using
an anti-p70S6K Thr389 antibody.
In vitro raptor phosphorylation
Mutation of pEBG6/raptor (DSTT, University of Dundee) was
carried out at the indicated sites using site-directed mutagenesis
to generate triple alanine mutants of Ser855/859/863 and Ser877/881/885.
HEK293T cells were cultured in 10 cm plates and 5 μg of
plasmid (both wt and mutant) transfected using 25 μg of PEI per
plate as a transfection reagent. The following day, cells
were lysed as described above. GST-tagged raptor was
immunoprecipitated in duplicate from 1 mg of lysate for
2 h using 20 μl of glutathione–Sepharose 4 Fast Flow (GE
Healthcare). Protein–bead complexes were washed twice in
lysis buffer containing an additional 0.5 M sodium chloride
and twice in wash buffer (50 mM Tris/HCl, pH 7.5, 0.1 mM
EGTA and 0.1% β-mercaptoethanol). Beads were resuspended
in a final volume of 50 μl of assay buffer {50 mM
Tris/HCl, pH 7.5, 0.1 mM EGTA and 0.1% β-mercaptoethanol,
50 mM magnesium acetate, recombinant GSK3β (DSTT,
University of Dundee), 100 μM non-radiolabelled ATP and
2.7 μCi of [32P]ATP} and incubated on a shaker for 30 min at
30 ◦C. Reactions were boiled with 10 μl of 6× Laemmli buffer for
15 min and 30 μl of separated by SDS/PAGE and transferred on to
PVDF membrane, as described above. Incorporation of [32P]ATP
was detected using exposure to radiographic film. Following this,
membranes were blocked and probed with anti-GST antibody to
confirm equal protein loading.
Statistical analysis
Statistical analysis was performed using GraphPad Prism. Data
are presented as means +− S.E.M. with quantitative graphics and
statistical assessments being derived from a minimum of three
biological replicates per group. Values used to normalize results
in each assay were excluded from statistical analysis, which
involved ANOVA and Tukey’s post-test for multiple comparisons.
Significance was set at a P-value of <0.05.
RESULTS
Pharmacological inhibition of GSK3 suppresses mTORC1 signalling
mTORC1-directed signalling is critically dependent upon AA
availability and, as shown in Supplementary Figures S1(A) and
S1(B), can be rapidly down- or up-regulated in cells irrespective
of their lineage when they are subjected to withdrawal or resupply
of extracellular AAs respectively. In an attempt to study whether
GSK3 participates in the regulation of mTORC1 signalling, we
initially investigated the effect of GSK3 inhibition upon AA-
dependent phosphorylation of downstream mTORC1 substrates.
Consistent with the findings shown in Supplementary Figure S1,
the data presented in Figures 1(A)–1(C) indicate that subjecting
L6 myotubes, HEK293T and HeLa cells to a 60-min period of AA
depletion promotes a significant reduction in phosphorylation of
p70S6K1Thr389 and 4E-BP1Thr37/46, whereas subsequently refeeding
cells with a physiological 1× AA mix re-instates phosphorylation
of both proteins to a level comparable to that seen in AA-replete
cells. The phosphorylation status of ribosomal S6 is respectively
down- and up-regulated when cells were either AA-deprived or-
refed following AA depletion. The ability of AAs to promote
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Figure 1 Effect of GSK3 inhibitors on mTORC1 signalling in L6 myotubes, HeLa and HEK293T cells
(A–C) Cells were held in EBSS containing or lacking AAs for 1 h or alternatively having been depleted of AAs incubated in EBSS containing a 1× AA mix (refeed) for 15 min. Cells were incubated
with 100 nM rapamycin, 50 μM SB415286 or 30 μM roscovitine for 15 min prior to and for 15 min during the AA-refeed period. Cells were lysed and 30 μg of lysate protein was analysed by
immunoblotting. Blots shown in (A–C) are representative of a minimum of three independent experiments and histograms (means +− S.E.M., *P < 0.05) show quantification of these. (D) L6 myotubes
were AA-depleted for 1 h in EBSS followed by incubation in EBSS + AA for 15 min in the absence or presence of 50 μM SB415286, 10 μM SB216763, 30 μM roscovitine, 40 μM CT99021 or
100 nM rapamycin for 0.5 h. Cells were harvested and 30 μg of protein was analysed by immunoblotting using the antibodies indicated. (E) HEK293T cells were subjected to AA-depletion/refeeding
as in (A–C) or incubated with EBSS supplemented with serum [10 % (v/v) FBS] +− 100 nM rapamycin or 50 μM SB415286 for 0.5 h, as indicated. Cells were lysed and 30 μg of protein was
analysed by immunoblotting using the antibodies indicated.
p70S6K1Thr389 and S6Ser240/244 phosphorylation in all three cell
lines was severely blunted by the mTOR inhibitor rapamycin
(Figures 1A–1C). Although the AA-induced phosphorylation of
4E-BP1Thr37/46 was also blunted by rapamycin, the effect of the
inhibitor on 4EBP-1 phosphorylation was not as potent as that
on p70S6K1Thr389 phosphorylation in HeLa or HEK293T cells
(Figures 1B and 1C). This finding is consistent with previous
reports indicating that mTORC1 substrates, such as p70S6K1
and 4E-BP1, exhibit differential sensitivity towards rapamycin
[27]. Strikingly, SB415286, a potent and selective cell-permeant,
ATP-competitive inhibitor of GSK3α and GSK3β [28,29], also
caused strong repression of the AA-induced phosphorylation of
p70S6K1 and S6. Again, whereas AA-induced phosphorylation of
4E-BP1Thr37/46 was sensitive to SB415286, the observed inhibition
was modest in comparison with that seen for p70S6K1 and S6.
Since SB415286 has been shown to also inhibit members of the
CDK family in in vitro-based kinase assays [30] and CDK1/cdc2
may modulate raptor phosphorylation [18], we also assessed the
effects of roscovitine, a potent cdc2, CDK2 and CDK5 inhibitor
[31], which does not inhibit GSK3 (Supplementary Figure S2A).
Figures 1(A–C) show that, unlike rapamycin or SB415286,
roscovitine did not attenuate AA-induced phosphorylation of
mTORC1/S6K1 targets. The efficacy of roscovitine as a CDK
inhibitor was confirmed in separate experiments demonstrating
a reduction in immunoprecipitable CDK5 activity (results not
shown). We also assessed the effect of two additional, but
structurally distinct, GSK3 inhibitors, SB216763 and CT99021
[30]. Figure 1(D) shows that these GSK3 inhibitors also exerted
a repressive effect on AA-induced mTORC1 signalling in L6
myotubes, thus strongly implicating GSK3 in the regulation of
mTORC1 activity.
Although AA provision alone is an important stimulus
for mTORC1, it is well recognized that activation of the
complex is further enhanced by the presence of serum growth
factors. Figure 1(E) shows that AA-induced phosphorylation of
p70S6K1Thr389 by mTORC1 was augmented in HEK293T cells
exposed to serum, but that this enhanced stimulation remains
sensitive to SB415286. In contrast, it is noteworthy that SB415286
did not suppress serum-induced phosphorylation of the Ser473 site
on Akt, which serves as a target for mTORC2 (Figure 1E, inset).
It is important to stress that HEK293T cells exhibit elevated Akt
activity in the basal (unstimulated) state [32] and for this reason
any enhancement in Akt or p70S6K1 phosphorylation induced by
serum treatment of these cells appears modest (Figure 1E).
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Figure 2 Effects of shRNA-mediated gene silencing of GSK3α/β upon mTORC1-directed signalling
(A) Total RNA was extracted from L6 myotubes stably expressing either a non-specific shRNA or shRNAs targeting GSK3α and GSK3β . cDNA was synthesized from the mRNA and relative GSK3
mRNA abundance, as measured against GAPDH mRNA, assessed by quantitative PCR. (B) Lysates were prepared from L6 myotubes stably expressing either a non-specific shRNA or shRNAs
targeting GSK3α and GSK3β . A 30 μg amount of lysate was analysed by immunoblotting using anti-GSK3α/β or anti-GAPDH antibodies. In addition, 100 μg of lysate was also subjected to
immunoprecipitation using antibodies against either GSK3α or GSK3β and analysis of the respective GSK3 activities carried out using a phospho-GS peptide as a substrate. (C) L6 myotubes stably
expressing either a non-specific shRNA or shRNAs targeting GSK3α and GSK3β were held in EBSS containing or lacking AA for 1 h or alternatively having been depleted of AAs incubated in EBSS
containing a 1× physiological AA mix (refeed) for 15 min in the absence or presence of 50 μM SB415286. Cells were harvested and 30 μg of lysate was analysed by immunoblotting using the
antibodies indicated. The asterisk indicates a significant (P < 0.05) change between the indicated bars.
Muted mTORC1 signalling in GSK3-silenced cells
To further substantiate the involvement of GSK3 in mTORC1
signalling, we utilized lentivirus-based shRNA technology to
generate L6 myotubes exhibiting stable knockdown of both
GSK3α and GSK3β. Figure 2(A) shows that the relative mRNA
abundance for each GSK3 isoform was reduced by up to ∼85%
by GSK3 shRNA, which resulted in substantial (∼90%) depletion
of GSK3α and GSKβ protein and immunoprecipitable isoform-
specific GSK3 activity (Figure 2B). Analysis of p70S6K1Thr389
and S6Ser240/244 phosphorylation revealed that, although cells
expressing the control shRNAs exhibit the classical inhibitory and
stimulatory response to AA withdrawal and resupply respectively,
these responses were significantly reduced in shRNA GSK3-
silenced cells (Figure 2C), suggesting that GSK3 activity is
required to support mTORC1 signalling.
It is plausible that the reduced activation of mTORC1 signalling
that we observe in GSK3 inhibitor-treated cells or those in
which we have stably silenced GSK3α/β expression may be a
consequence of reduced uptake of extracellular AAs. However,
analysis of AA uptake and expression of LAT1 (SLC7A5) and
the SNAT2 (SLC38A2) transporter reveals that for the latter there
was no change in transport activity as a result of silencing GSK3,
whereas uptake and accumulation of leucine (a potent activator
of mTORC signalling [33]) by the former was actually elevated
under conditions when GSK3 activity is inhibited (Supplementary
Figure S3).
Effects of GSK3 inhibition upon cellular autophagy, protein
synthesis and cell proliferation
In addition to p70S6K1 and 4E-BP1, mTORC1 can
also phosphorylate the ULK1 protein kinase complex and
TFEB, which are respectively involved in the formation of
autophagosomes and expression of autophagy and lysosomal
genes [34–37]. During AA sufficiency, mTORC1 phosphorylates
both ULK1 (thereby suppressing autophagsome formation) and
TFEB (which promotes cytosolic retention and thus reduced
expression of lysosomal genes). In contrast, mTORC1 inhibition
stimulates autophagy and nuclear localization of TFEB as a
consequence of its reduced phosphorylation. Consistent with this
modus operandi, we found that when HeLa cells were subject to
AA depletion, there was a modest increase in nuclear localization
of GFP-labelled TFEB, whereas refeeding cells with AAs after
the depletion period led to significantly greater retention of the
transcription factor to the cytosol (Figure 3A). This AA-induced
cytosolic retention of TFEB was not apparent in cells treated with
either rapamycin or SB415286 during the AA-repletion phase,
indicative of mTORC1 inhibition (Figure 3A).
Under conditions of nutrient sufficiency, phosphorylation of
ULK1Ser757 by mTORC1 is important for inhibiting autophagy
induction [38]. Phosphorylated ULK1Ser757 was detected in HeLa
cells, L6 myotubes as well as U2OS cells (a human osteosarcoma
cell line) when incubated in AA-containing buffer. A marked
loss in ULK1Ser757 phosphorylation was observed when cells were
AA-depleted, but this was rapidly reversed upon cellular AA
repletion. This AA-induced rephosphorylation of ULK1Ser757 was
blunted if either rapamycin or SB415286 (but not roscovitine)
were present in the AA-repletion buffer (Figure 3B). To assess
whether autophagy was induced under these latter circumstances,
we monitored the formation of autophagosomes in U2OS
cells by visualizing LC3 puncta by immunofluorescence in the
absence or presence of the lysosomal proton pump inhibitor, or
bafilomycin A1. The inhibitor facilitates an increase in lysosomal
pH that helps suppress degradation of autolysosome content,
permitting accumulation of LC3-positive autophagosomes as
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Figure 3 Effects of AA depletion/repletion and GSK3 inhibition upon markers of lysosomal biogenesis and autophagy
(A) HeLa cells were cultured on coverslips and transfected with GFP-tagged TFEB. Twenty-four hours post transfection, cells were incubated in EBSS and EBSS + AA in the absence or presence of
100 nM rapamycin or 50 μM SB415286 as indicated and cells were fixed, imaged and analysed as described in the Materials and methods section. Asterisks indicate significant (P < 0.05) changes
between indicated bars. (B) HeLa cells, L6 myotubes and U2OS cells were subjected to incubation with EBSS containing or lacking AAs for 1 h or alternatively having been depleted of AAs incubated
in EBSS containing a 1× AA mix (refeed) for 15 min in the absence/presence of 100 nM rapamycin, 50 μM SB415286 or 30 μM roscovitine as indicated. Cells were lysed and 30 μg of lysate
protein was analysed by immunoblotting. (C) U20S cells were incubated as in (B) but in the absence or presence of 50 nM bafilomycin A1. Cells were fixed and nuclei (blue DAPI) and LC3 puncta
(green fluorescence) visualized as described in the Materials and methods section. Asterisks indicate a significant difference between the indicated bars (A) or indicate a significant difference in LC3
puncta observed relative to the untreated AA-sufficient control (P < 0.05).
evidence of efficient autophagic flux. Figure 3(C) shows a
significant increase in LC3 puncta formation (i.e. autophagy,
depicted as green staining) when U2OS cells were subject to
AA depletion, which was repressed upon AA resupply following
nutrient deprivation. This repression was strongly attenuated
under circumstances when mTORC1 signalling was suppressed
either directly by rapamycin or via inhibition of GSK3 using
SB415286 (Figure 3C).
Since mTORC1 positively influences protein synthesis, we
explored whether this anabolic process would be affected in
cells treated with SB415286. We utilized an anti-puromycin
antibody to measure the incorporation of puromycin, a tyrosine-
tRNA mimetic, into newly synthesized proteins as readout
for this process. As expected, we observed no labelling of
proteins in the absence of puromycin (Figure 4A, lane 1) or
when cells were incubated with cycloheximide, which would
effectively preclude incorporation of puromycin into nascent
proteins through its ability to inhibit translocation of mRNA on
80S ribosomes (lane 7). Relative to cells held in AA-containing
medium (lane 2) the abundance of puromycylated proteins in
AA-deprived cells (lane 3) was reduced consistent with a
reduction in protein synthesis that might be expected under
nutrient-starved conditions. AA resupply in the absence or
presence of insulin (lanes 4 and 5) led to a notable increase in
puromycylated proteins that was clearly suppressed if cells had
been pre-treated with SB415286 (lane 6). In line with this latter
finding, the effects of sustained cell incubation with SB415286
(or rapamycin) were also found to reduce cell proliferation by
∼60% compared with vehicle-treated cells (Figure 4B). This
latter finding is in keeping with very recent work showing that four
different GSK3 inhibitors (SB216763, AR-A01148, CT99012 and
L803-mts) also suppress, by a similar magnitude, the proliferative
capacity of MCF-7 cells [19].
GSK3 inhibition does not affect lysosomal mTOR localization or
modify expression of core mTORC1 signalling proteins
Having established that pharmacological inhibition of GSK3 or
cellular shRNA-induced depletion of GSK3α and GSK3β results
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Figure 4 Effect of SB415286 on protein synthesis and cell growth
(A) HeLa cells were incubated in EBSS containing or lacking AA for 3 h or alternatively having been depleted of AAs incubated in EBSS containing 1× AA mix (refeed) +− 100 nM insulin for 30 min.
Cells were incubated with 50 μM SB415286 or 50 μg/ml cycloheximide during the AA depletion and refeed period. Puromycin (1 μM) was added 30 min prior to cell harvest. Cells were lysed
and 30 μg of protein was analysed by immunoblotting using antibodies against puromycin or the proteins indicated. (B) HEK293T cells were seeded at a density of 3.5 × 104 and treated 24 h
post-seeding with vehicle solution and either 100 nM rapamycin or 50 μM SB415286 for up to 72 h. Cell number was quantified as described in the Materials and methods section.
in reduced nutrient-dependent mTORC1 signalling, we attempted
to elucidate the basis on which the latter was dependent on
GSK3. AA deprivation has been reported to release mTOR
from lysosomal membranes, whereas nutrient resupply induces
lysosomal re-engagement and activation of the mTORC1
complex [6,39]. To test whether loss of mTORC1 signalling
as a consequence of GSK3 inhibition was associated with a
disruption in lysosomal mTOR targeting, we compared mTOR
localization with that of LAMP2 (a lysosomal protein marker) by
immunofluorescence in HeLa cells. Figure 5 shows that, in line
with findings from other groups [6], AA depletion caused a net
reduction in lysosomal mTOR localization that was restored upon
AA refeeding of cells. Intriguingly, whereas both rapamycin and
SB415286 suppress nutrient-dependent mTORC1 signalling, this
does not involve reduced lysosomal targeting of mTOR which,
unexpectedly, we found to be enhanced by both inhibitors during
cellular AA repletion. The reasons for this increase in lysosomal
mTOR are unclear, but may form part of a feedback mechanism
attempting to enhance mTORC1 signalling at the lysosome
in response to a reduction in phosphorylation of downstream
mTORC1 targets.
Figures 6(A) and 6(B) show that the reduction in mTORC1
signalling observed in cells treated with SB415286 (Figure 1) or
GSK3 shRNA (Figure 2C) could not be attributed to gross changes
in the expression of mTOR, raptor or PRAS40. Previous work
has indicated that raptor dissociation from mTOR contributes
to the mechanism by which rapamycin induces inhibition of
mTOR function [40]. Immunoprecipitation of mTOR from
HEK293T cells led to co-precipitation of raptor and mLST8
which was unaffected by the AA status of the incubation
buffer (Figure 6C). However, subjecting cells to incubation with
rapamycin led to a noticeable reduction in raptor co-precipitation,
indicating a weakening of the mTOR–raptor interaction [41].
We also detected reduced raptor–mTOR association following
cell treatment with SB415286 although less robustly than that
seen in cells treated with rapamycin. Rapamycin, Ku-0063794
(which inhibits both mTORC1 and mTORC2 [42]) and SB415286
also reduced mTOR–raptor interaction when assessed in FLAG
immunoprecipitates from HEK293T cells expressing wt FLAG–
raptor (Figure 6D).
GSK3 mediates raptor phosphorylation on Ser859 and influences
raptor–mTOR association
mTOR signalling can be regulated by stimulus-induced
phosphorylation of raptor as seen, for example, in response to
hormonal, nutritional and osmotic cues [15,43,44]. To assess
whether raptor was a potential GSK3 target, we initially
performed in silico analysis for putative GSK3 phosphorylation
motifs on raptor. Our motif analysis revealed the presence of two
putative GSK3 cluster sites (cluster 1: Ser855, Ser859, Ser863 and
cluster 2: Ser877, Ser881, Ser885) that map to its central region
and which are conserved in human, mouse and rat raptor
homologues (Figure 7A). We subsequently expressed wt GST-
tagged raptor or raptor constructs in which the serine residues in
each identified cluster had been mutated to alanine in HEK293T
cells. Expressed GST–proteins were then immunoprecipitated and
used as substrates in a GSK3β kinase in vitro assay. Figure 7(B)
shows that GSK3β-mediated phosphorylation of raptor was
reduced significantly (>50%) when serine residues within the
first, but not second, cluster were changed to alanine. To identify
whether any of the raptor residues identified by in silico analysis
were bona fide GSK3 phosphorylation sites, we performed LC–
MS/MS analysis of raptor immunoprecipitated from HEK293T
cells incubated in medium containing or lacking SB415286. Our
analysis yielded 58% and 60% sequencing coverage in the
untreated control and SB415286 samples respectively with all
phosphosites localizing to the correct location on the peptides
with a greater than 90% probability. Figure 7(C) shows that of
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Figure 5 Effect of SB415286 and rapamycin on mTOR localization
HeLa cells were cultured in EBSS containing or lacking AA or alternatively having been depleted of AAs incubated in EBSS containing a 1× AA mix (refeed) for the times indicated. In some cases, cells
were incubated with 100 nM rapamycin or 50 μM SB415286 for 15 min prior to and for 10 min during the AA-refeed period as indicated. Cells were fixed, and fluorescent labelling and quantification
of mTOR co-localization with LAMP2 was carried out as described in the Materials and methods section. Image quantification (means +− S.E.M.) is based on data from at least ten different fields of
view. Asterisks indicate significant (P < 0.05) differences between indicated bars.
Figure 6 Effects of GSK3 inhibition or shRNA-mediated GSK3α/β silencing on expression of proteins involved in mTOR signalling
(A and B) L6 myotubes were either held in EBSS containing or lacking AAs for 1 h or alternatively, having been AA-depleted, incubated in EBSS containing a 1× AA mix (refeed) for 15 min. Cells were
incubated with 100 nM rapamycin, 50 μM SB415286 or 30 μM roscovitine for 15 min prior to and for 15 min during the AA-refeed period as indicated prior to cell lysis. Alternatively, L6 myotubes
stably expressing non-specific shRNA or shRNAs targeting GSK3α/GSK3β were lysed for analysis. A 30 μg amount of lysate was analysed by immunoblotting using the antibodies indicated.
(C) Effect of GSK3 inhibition on raptor and mLST8 association with mTOR and 4E-BP1 phosphorylation. HEK293T cells were incubated in EBSS lacking or containing AAs and inhibitors as in
(A). Cells were lysed, the lysate was used to immunoprecipitate mTOR, and immunoprecipitates were analysed for proteins indicated. Alternatively, 30 μg of lysate was used for SDS/PAGE and
immunoblot analysis of 4E-BP1 or tubulin (gel loading control). (D) HEK293T cells overexpressing FLAG–raptor were incubated with EBSS +− AAs as described in (A) above and with 100 nM
rapamycin, 50 μM SB415286 or 1 μM Ku-0063794, as indicated. Cells were lysed and raptor was immunoprecipitated using anti-FLAG antibodies prior to immunoblotting with anti-mTOR and
anti-FLAG antibodies.
the phospho-sites identified by LC–MS/MS analysis, three of
these, Ser859, Ser863 and Ser877, are located within the two clusters
identified by motif analysis. Ser855 in cluster 1 and Ser881 and
Ser885 in cluster 2 identified as putative GSK3 phosphorylation
sites were not identified by LC–MS/MS as sites phosphorylated
on raptor in our cells. Two additional phospho-sites out with these
clusters, Ser791/792 and Ser722, were also detected. Of the residues
detected by LC–MS/MS, only phosphorylation of Ser859 was lost
following cell treatment with SB415286 (Figure 7C).
Phosphorylation of substrates by GSK3 is unusual in that the
kinase has a strong preference for substrates that have already
undergone a priming phosphorylation event at residue 4 or 5 AAs
C-terminal to the GSK3 target site [45]. Based on the finding that
Ser863 was identified as a phosphorylated residue and is located
four residues C-terminal to Ser859, we postulated that Ser863 may
serve as the priming site. To test this proposition we expressed
FLAG-tagged wt raptor and FLAG-tagged raptor mutant (S863A
and S859A) constructs in HEK293T cells (Figure 8A). The
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Figure 7 Identification of GSK3-mediated raptor phosphorylation sites
(A) Alignment of AA sequence of raptor in Homo sapiens, Mus musculus and Rattus norvegicus showing conserved putative GSK3 serine phosphorylation sites. (B) HEK293T cells over expressing
either GST-tagged wt raptor or GST-tagged mutant raptor were lysed, and GST-tagged raptor was immunoprecipitated. Phosphorylation of the tagged raptor proteins by GSK3β was analysed as
described in the Materials and methods section. Analysis of gel loading was confirmed by subsequent blotting of the membrane using anti-GST antibody. *P < 0.05, significant difference in the ratio
of phosphorylation to total GST–raptor compared with wt raptor. (C) HEK293T cells were incubated for 1 h in EBSS containing AAs in the absence or presence of 50 μM SB415286. Cells were lysed
and phosphorylation of raptor was analysed by MS, as described in the Materials and methods section.
FLAG–raptor proteins were immunoprecipitated using anti-
FLAG antibodies and the precipitates screened using phospho-
specific antibodies against Ser863 and Ser859. Figure 8(A) (lower
panel) shows that we were unable to detect phosphorylation of
either Ser863 or Ser859 in FLAG–raptor S863A immunoprecipitates,
whereas only phosphorylation of Ser863 was observed in FLAG–
raptor S859A immunoprecipitates. Phosphorylation of both sites
was detected in lysates from cells transfected with wt raptor. These
findings are consistent with the idea that phosphorylation of Ser863
most probably serves to prime raptor phosphorylation of Ser859 by
GSK3.
Previous studies have reported that, when activated, mTOR
mediates phosphorylation of raptor on Ser863 [15,43]. To
test whether mTOR acts as the priming kinase for Ser859
phosphorylation, we immunoprecipitated FLAG–wt raptor
from HEK293T cells subjected to AA depletion/resupply in
the absence and presence of mTOR and GSK3 inhibitors. We
observed a reduction in both Ser863 and Ser859 phosphorylation
when cells were AA depleted for 60 min which was associated
with an attendant reduction in p70S6KThr389 phosphorylation
(Figure 8B, upper and lower panels). The loss in phosphorylation
of both raptor sites and that of p70S6K1Thr389 was reversed
upon acute AA refeeding of cells. Surprisingly, although
p70S6K1Thr389 phosphorylation was strongly suppressed by
treatment of cells with rapamycin and Ku-0063794 during
the AA-repletion phase, neither mTOR inhibitor prevented the
AA-induced increase in Ser863 and Ser859 phosphorylation. In
contrast, SB415286 blocked phosphorylation of Ser859 without
causing any detectable loss of Ser863 phosphorylation and also
diminished phosphorylation/activation of p70S6K1 (Figure 8B).
These observations imply that phosphorylation of Ser863 and
Ser859 can be regulated in an AA-dependent manner and that,
although neither serves as an mTOR target site, phosphorylation
of Ser859 may be necessary for mTORC1-directed signalling.
Since insulin also positively regulates mTORC1 signalling via
the Akt–TSC2–Rheb axis, we assessed whether phosphorylation
of Ser863 and Ser859 was modulated by insulin and, if so,
whether this was also sensitive to SB415286. Figure 8(C) shows
that, although insulin causes a robust increase in p70S6KThr389
phosphorylation, the hormone has no detectable effect on
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
Regulation of mTORC1 signalling by GSK3 217
Figure 8 Effects of AA and insulin on raptor and p70S6K1 phosphorylation
(A) HEK293T cells overexpressing FLAG–raptor, FLAG–raptor S859a or FLAG–raptor S863A mutant were lysed and FLAG-conjugated proteins were immunoprecipitated using anti-FLAG antibodies.
Immunoprecipitates and 30 μg of lysate respectively were analysed by immunoblotting for the proteins indicated. (B) HEK293T cells overexpressing FLAG–raptor were incubated in EBSS containing
or lacking AA for 1 h or alternatively having been depleted of AAs incubated in EBSS containing 1× AA mix (refeed) for 15 min. Cells were incubated with 100 nM rapamycin, 50 μM SB415286 or
1 μM Ku-0063794 for 15 min prior to and for 15 min during the AA-refeed period where indicated. Cells were harvested and 30 μg of protein was analysed by immunoblotting using the antibodies
indicated. The lower panel represents quantification of Ser863 and Ser859 phosphorylation from at least three separate experiments (means +− S.E.M.) (C) HEK293 cells overexpressing FLAG–raptor
were incubated in EBSS containing or lacking AA for 1 h +− 100 nM insulin (15 min) or alternatively having been depleted of AAs incubated in EBSS containing 1× AA mix (refeed) for 15 min +−
100 nM insulin. Cells were incubated with 50 μM SB415286 for 15 min prior to and for 15 min during the AA refeed period where indicated. Cells were harvested and 30 μg of protein was analysed
by immunoblotting using the antibodies indicated.
the phosphorylation of Ser863 and Ser859 in HEK293 cells
over-expressing FLAG-tagged wt raptor (compare lanes 1
and 7). Irrespective of whether insulin was present or
not, phosphorylation of Ser859 (but not Ser863) was reduced
substantially by the presence of SB415286 and, under these
circumstances, we also observed an attendant reduction in
p70S6KThr389 and 4E-BP1 phosphorylation (compare lanes 5 and
6 as well as lanes 8 and 9).
The data presented in Figures 6(C) and 6(D) support the
possibility that GSK3 inhibition and raptor phosphorylation of
Ser859 may influence mTORC1 signalling by modulating the
interaction between raptor and mTOR. To test this possibility
further, we expressed FLAG-tagged constructs of wt raptor
and S859A in HEK293T cells and assessed mTOR activity
in FLAG immunoprecipitates. Figure 9(A) shows that the
abundance of mTOR was noticeably reduced in FLAG–Raptor
S859A precipitates compared with that in wt raptor precipitates.
Subsequent analysis of mTOR activity associated with the FLAG
immunoprecipitates (using recombinant kinase-dead p70S6K as
substrate) demonstrated a near 50% reduction in mTOR activity
in FLAG–Raptor S859A precipitates (Figure 9B), consistent with
the reduced amount of mTOR associated with the mutated raptor
protein (Figure 9A). In contrast, we observed no detectable
difference in association of p70S6K1 with wt raptor or the S859A
raptor (Figure 9C). This latter observation is entirely consistent
with previous work showing that raptor S859A and S863A
mutants retain normal capacity for interaction with 4E-BP1, but
that mTOR activity associated with the S863A mutant is severely
blunted [43]. Compared with HEK293T cells expressing FLAG–
wt raptor, those transfected with Flag–Raptor S859A exhibit
reduced p70S6K1 phosphorylation (Figure 9D). This finding is
in line with the idea that, although the S859A raptor mutant has
reduced capacity for interaction with mTOR, it would compete
with native raptor for association with mTORC1 and raptor-bound
substrates and thereby reduce the pool of these substrates available
for mTOR-catalysed phosphorylation.
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Figure 9 Raptor–mTOR–S6K1 association and mTORC1 signalling
(A) HEK293T cells overexpressing FLAG–raptor or FLAG–raptor S859A were lysed and FLAG-tagged raptor variants were immunoprecipitated using anti-FLAG antibodies. Immunoprecipitates
were analysed by immunoblotting using antibodies against mTOR and FLAG. Three separate experiments were performed. The histogram shows quantification of mTOR co-immunoprecipitated
with wt and S859A mutant FLAG–raptor. (B) HEK293T cells overexpressing FLAG–raptor or FLAG–raptor S859A mutant were lysed and raptor was immunoprecipitated using anti-FLAG antibody.
Raptor-associated mTOR kinase activity was assayed as described in the Materials and methods section using kinase-inactive recombinant p70S6K1 as substrate followed by immunoblotting using
the antibody against phospho-70S6K1. The histogram shows quantification of p70S6K phosphorylation in relation to immunoprecipitated wt and S859A mutant FLAG–raptor. (C) HEK293T cells
overexpressing FLAG–raptor or FLAG–raptor S859A were incubated for 1 h in EBSS containing 1× AA mix. Cells were lysed and FLAG-tagged raptor variants were immunoprecipitated using
anti-FLAG antibody. Immunoprecipitates were analysed by immunoblotting for the proteins indicated. The histogram shows quantification of p70S6K that is co-immunoprecipitated with wt and
S859A mutant FLAG–raptor from three independent experiments. (D) HEK293T cells overexpressing FLAG–raptor or FLAG–raptor S859A mutant were lysed and 30 μg of protein was analysed by
immunoblotting for the proteins indicated.
DISCUSSION
Hitherto, the idea that GSK3 may influence mTORC1 signalling
has primarily been based on evidence indicating an indirect
regulatory input that the kinase has upon this key nutrient
signalling axis. The co-ordinated phosphorylation and activation
of TSC2 by AMPK and GSK3, for example, has been reported
to negatively regulate mTORC1 signalling [46]. However, there
is also evidence showing that GSK3 promotes S6K1 activation
in different cell lines by phosphorylating the kinase on Ser371
within its turn motif, which subsequently enhances Thr389
phosphorylation by mTOR [47]. It is unclear whether these
contrasting observations stem from differences in cell type or
cellular context, but recent studies in MCF-7 breast cancer cells
demonstrate that GSK3 positively enhances mTORC1 activity
and that this stimulatory effect correlates with increased cell
growth and proliferation [19]. Although this latter study did not
reveal how GSK3 enhanced mTORC1 activity, our observation
that GSK3 inhibition suppresses phosphorylation of numerous
mTORC1 substrates in multiple cell lines provides yet further
support for the view that GSK3 generally conveys a net positive
input into the regulation of mTORC1 activity. Furthermore, our
subsequent investigation reveals for the first time that it does so
by acting directly upon raptor.
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Figure 10 Scheme showing GSK3 involvement in the regulation of mTORC1-directed signalling
AA provision regulates RAG-mediated recruitment of the mTORC1 complex to the lysosomal membrane, but also induces phosphorylation of the mTOR scaffold protein raptor on Ser863 by an
unknown kinase. Phosphorylation of Ser863 primes phosphorylation of Ser859 by GSK3, which supports mTOR–raptor interaction and mTOR-catalysed phosphorylation of multiple downstream
targets such as ULK1 and TFEB (thereby suppressing autophagy/lysosomal biogenesis) and p70S6K1 and 4E-BP1 (which support cell growth and proliferation). GSK3 inhibition leads to a loss in
raptor Ser859 phosphorylation, reduced mTOR and raptor association and concomitant reduction in mTORC1-directed signalling. Activation of mTORC1 is subject to enhancement by insulin that
induces activation of the mTORC1 complex via the Akt–TSC2–Rheb axis. This axis appears not to influence raptor phosphorylation on Ser863 or Ser859.
Although considerable progress has recently been made
in identifying the many proteins involved in signalling AA
sufficiency to mTORC1, there is growing appreciation that
modulation of raptor phosphorylation on specific sites may
serve an important ‘gate-keeping’ function that either promotes
or inhibits mTORC1 signalling. Raptor possesses a unique
conserved N-terminal half known as the RNC (raptor N-terminal
conserved) domain that is followed by a central region containing
three HEAT domains and then seven WD40 repeats near the
C-terminus [48]. In response to nutrient/energy deprivation for
example, AMPK activation results in direct phosphorylation
of raptor on residues (Ser722 and Ser792) located within its
central region. Phosphorylation of these sites leads to raptor
association with 14-3-3 protein and consequential loss of
mTORC1 signalling that, in turn, induces cell cycle arrest [17].
In contrast, phosphorylation of raptor on other serine sites within
the central region is considered to be important for promoting
mTOR signalling in response to mitogenic and oncogenic
activation of the Ras–MAPK pathway [16,49] and for facilitating
cell cycle G2/M transition when raptor is phosphorylated by
cdc2 [18,20]. Our findings demonstrate, for the first time, that
raptor is also subject to phosphorylation on Ser859 by GSK3
and that phosphorylation of this site supports AA-dependent
phosphorylation of multiple mTORC1 targets. In line with
previous work [15,43], we find that phosphorylation of Ser859
is critically dependent upon phosphorylation of Ser863, which we
believe primes raptor for phosphorylation on Ser859 by GSK3.
Since GSK3 is normally active in cells [50] and we find no
evidence of it being regulated by changes in AA availability
(Supplementary Figure S2), the AA-dependent phosphorylation
of Ser859 most probably tracks that of Ser863 by an AA-regulated
kinase activity. Although evidence exists in the literature showing
that mTOR can mediate phosphorylation of Ser863 [15,43], the
observation that neither rapamycin nor Ku-0063794 (mTOR
inhibitors) suppress phosphorylation of Ser863 in our hands implies
that this site is targeted by another, as yet unknown, kinase(s)
whose activity may be regulated in an AA-dependent manner.
The finding that enhanced raptor phosphorylation of Ser863 in
response to osmotic stress in HEK293 cells [44] or in contracting
skeletal muscle [51] is insensitive to rapamycin strongly indicates
the presence of a regulatable Ser863 kinase. Alternatively, the
enhanced phosphorylation status of Ser863 in response to nutrient
provision/osmotic stress may be critically dependent upon the
inactivation of a phosphatase that normally targets this residue.
Understanding how Ser863 phosphorylation may be modulated
(i.e. whether it involves an AA-regulated priming kinase or
c© 2015 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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phosphatase) represents an important investigative goal of future
work if we are to fully understand how AAs enhance mTORC1
signalling.
The notion that GSK3 activity is required for supporting
mTORC1-directed nutrient signalling may seem counter-
intitutive, given that insulin promotes mTORC1 activation via
the Akt–TSC2–Rheb axis whilst inducing phosphorylation and
inhibition of GSK3 by an Akt-dependent mechanism. This
apparent paradox may be explained on the basis that either
(i) insulin targets a discrete subcellular pool of GSK3 that
is not directly linked to regulation of the mTORC1 complex,
and/or (ii) the extent to which the hormone inhibits GSK3 is
insufficient to impact upon mTOR activity. Insulin only causes
a partial inactivation (∼30%) of GSK3 (Supplementary Figure
S2), which is substantially less than the 80–90% inhibition seen
in cells treated with SB415286 [52] or those subjected to shRNA-
mediated GSK3 depletion (Figure 2; Supplementary Figure S2)
in which we observe a major reduction in mTORC1 signalling to
an extent that mimics a state of nutrient insufficiency. This results
in suppressed protein synthesis and reduced phosphorylation of
substrates such as TFEB and ULK1 that promote a concomitant
increase in lysosomal/autophagosomal activity. This is illustrated
by our findings that GSK3 inhibition induces greater nuclear
localization of TFEB and enhances LC3 puncta formation and
is fully in keeping with other recent studies demonstrating that
inhibition of GSK3 stimulates lysosomal biogenesis by inducing
dissociation of TFEB from 14-3-3 protein and promoting its
nuclear localization [53,54]. Although Marchand et al. [54]
suggest that GSK3 and mTOR inhibition impinge independently
upon TFEB, inhibition of GSK3-mediated mTORC1 activity
has recently been shown by others to reduce cell proliferation,
increase lysosomal acidification and enhance autophagy in MCF-
7 human breast cancer cells [19].
Although previous work has demonstrated that a raptor S863A
mutant (in which there would also be an attendant loss of
Ser859 phosphorylation) is still able to interact with mTOR
[15,43], our data indicate that GSK3 inhibition or expression of
a S859A mutant significantly reduces raptor–mTOR association.
The affinity with which these two proteins interact is known to be
modulated in response to insulin and nutrient availability [41] and
so it is tempting to speculate that GSK3-mediated phosphorylation
of Ser859 may induce conformational changes in mTORC1 that
permit more effective engagement and phosphorylation of raptor-
bound mTOR substrates.
In summary, the present study demonstrates that GSK3 activity
is required for supporting mTORC1 signalling in response to
nutrient availability in a variety of cell types. We propose a model
in which GSK3 mediates phosphorylation of raptor on Ser859 and
suggest that this is crucially dependent upon phosphorylation of
Ser863 by an, as yet unknown, priming kinase that is likely to
be regulated in a nutrient-dependent manner. Phosphorylation of
Ser859 may stabilize the interaction between mTOR and raptor as
reduced phosphorylation of this site promotes their dissociation
and a fall in mTORC1-directed signalling (Figure 10). The
finding that GSK3 inhibitors suppress mTORC1 signalling and
promote lysosomal/autophagic activity thus offers additional
pharmacological opportunities for targeting growth/proliferation
of cells in which there is heightened mTORC1 activity.
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